Source comparison
Dosing Frequency and Exposure Duration: Continuous vs Pulsed
KPV has a short half-life. Most estimates place it at 30–90 minutes in circulation due to peptidase degradation. That means single-dose studies underestimate efficacy because tissue exposure drops rapidly after administration. Continuous or frequent dosing mai
This comparison does not assign a generated winner or score.
- KPV has a short half-life. Most estimates place it at 30–90 minutes in circulation due to peptidase degradation. That means single-dose studies underestimate efficacy because tissue exposure drops rapidly after administration. Continuous or frequent dosing maintains therapeutic concentrations long enough for downstream effects to manifest.
- In a wound healing model published in the Journal of Dermatological Science, topical KPV applied once daily reduced inflammatory markers (IL-6, TNF-α) within 24 hours, but wound closure rates didn't improve until day 5. The authors attributed the delay to the time required for reduced inflammation to translate into increased keratinocyte migration and collagen deposition. The peptide worked immediately at the cytokine level, but functional healing required sustained exposure over multiple days.
- Researchers designing KPV studies need to align dosing schedules with the biological endpoint they're measuring. If you're measuring cytokine suppression, a single dose followed by a 4-hour timepoint is sufficient. If you're measuring tissue repair, epithelial integrity, or disease activity scores, expect 48–96 hours of sustained dosing before effects become statistically significant. This isn't a KPV-specific limitation. It's true of any anti-inflammatory intervention targeting chronic tissue damage.